A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Clinical trial NCT06537414 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06537414
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-11
- Primary completion
- 2027-05-31
- Enrollment
- 283
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.